miRNA control of apoptotic programs: focus on ovarian cancer
暂无分享,去创建一个
Silvana Canevari | S. Canevari | D. Mezzanzanica | M. Bagnoli | L. Cecco | Delia Mezzanzanica | Loris De Cecco | Marina Bagnoli
[1] Sun-Mi Park,et al. miR-200c regulates induction of apoptosis through CD95 by targeting FAP-1. , 2010, Molecular cell.
[2] J C Reed,et al. IAP family proteins--suppressors of apoptosis. , 1999, Genes & development.
[3] Charles D. Johnson,et al. Genome-scale microRNA and small interfering RNA screens identify small RNA modulators of TRAIL-induced apoptosis pathway. , 2007, Cancer research.
[4] Xiaodong Wang,et al. Bid, a Bcl2 Interacting Protein, Mediates Cytochrome c Release from Mitochondria in Response to Activation of Cell Surface Death Receptors , 1998, Cell.
[5] R. Burger,et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. , 2006, The New England journal of medicine.
[6] Nicholas T. Ingolia,et al. Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.
[7] D. Bartel. MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.
[8] M. Peter. Let-7 and miR-200 microRNAs: Guardians against pluripotency and cancer progression , 2009, Cell cycle.
[9] E. Lengyel. Ovarian cancer development and metastasis. , 2010, The American journal of pathology.
[10] Hiroshi I. Suzuki,et al. Modulation of microRNA processing by p53 , 2009, Nature.
[11] S. Fulda,et al. Extrinsic versus intrinsic apoptosis pathways in anticancer chemotherapy , 2006, Oncogene.
[12] R. Agarwal,et al. Prognostic factors in ovarian cancer: how close are we to a complete picture? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[13] Junying Yuan,et al. Cleavage of BID by Caspase 8 Mediates the Mitochondrial Damage in the Fas Pathway of Apoptosis , 1998, Cell.
[14] W. El-Deiry,et al. Overview of cell death signaling pathways , 2005, Cancer biology & therapy.
[15] Carlo M Croce,et al. Apoptomirs: small molecules have gained the license to kill. , 2010, Endocrine-related cancer.
[16] S. Canevari,et al. c-FLIPL expression defines two ovarian cancer patient subsets and is a prognostic factor of adverse outcome. , 2009, Endocrine-related cancer.
[17] M. Lotze,et al. Apoptosis promotes early tumorigenesis , 2011, Oncogene.
[18] Muller Fabbri,et al. Modulation of miR-155 and miR-125b Levels following Lipopolysaccharide/TNF-α Stimulation and Their Possible Roles in Regulating the Response to Endotoxin Shock1 , 2007, The Journal of Immunology.
[19] George A Calin,et al. MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. , 2009, Cancer research.
[20] Huan Yang,et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN. , 2008, Cancer research.
[21] Robert A. Weinberg,et al. A Pleiotropically Acting MicroRNA, miR-31, Inhibits Breast Cancer Metastasis , 2009 .
[22] G. Perruolo,et al. Frontiers: PED/PEA-15, a multifunctional protein controlling cell survival and glucose metabolism. , 2009, American journal of physiology. Endocrinology and metabolism.
[23] J. Cleveland,et al. Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.
[24] B. Tsang,et al. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro , 2004, Oncogene.
[25] S. Canevari,et al. Sensitization of p53-mutated epithelial ovarian cancer to CD95-mediated apoptosis is synergistically induced by cisplatin pretreatment , 2007, Molecular Cancer Therapeutics.
[26] M. Kurokawa,et al. Caspases and Kinases in a Death Grip , 2009, Cell.
[27] Gregory J. Hannon,et al. microRNAs join the p53 network — another piece in the tumour-suppression puzzle , 2007, Nature Reviews Cancer.
[28] V. Ambros,et al. The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.
[29] H. Hermeking,et al. Frequent Downregulation of miR-34 Family in Human Ovarian Cancers , 2010, Clinical Cancer Research.
[30] S. Canevari,et al. CD95-Mediated Apoptosis Is Impaired at Receptor Level by Cellular FLICE-Inhibitory Protein (Long Form) in Wild-Type p53 Human Ovarian Carcinoma , 2004, Clinical Cancer Research.
[31] M. Birrer,et al. Ovarian Cancer: Markers of Response , 2009, International Journal of Gynecologic Cancer.
[32] S. Srinivasula,et al. Cytochrome c and dATP-Dependent Formation of Apaf-1/Caspase-9 Complex Initiates an Apoptotic Protease Cascade , 1997, Cell.
[33] Jing Wang,et al. Inhibition of c-FLIP expression by miR-512-3p contributes to taxol-induced apoptosis in hepatocellular carcinoma cells. , 2010, Oncology reports.
[34] Lalit Kumar,et al. Intraperitoneal Cisplatin and Paclitaxel in Ovarian Cancer , 2006, Indian Journal of Medical and Paediatric Oncology.
[35] A. Safa,et al. Cellular FLICE-like inhibitory protein (C-FLIP): a novel target for cancer therapy. , 2008, Current cancer drug targets.
[36] E. Kistner,et al. Let-7 expression defines two differentiation stages of cancer , 2007, Proceedings of the National Academy of Sciences.
[37] Muller Fabbri,et al. A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.
[38] Aimee L Jackson,et al. Coordinated regulation of cell cycle transcripts by p53-Inducible microRNAs, miR-192 and miR-215. , 2008, Cancer research.
[39] Sun-Mi Park,et al. CD95 promotes tumour growth , 2011, Nature.
[40] C. Lee,et al. MicroRNA and cancer – focus on apoptosis , 2008, Journal of cellular and molecular medicine.
[41] C. Croce,et al. MicroRNAs in Cancer. , 2009, Annual review of medicine.
[42] Joel Greshock,et al. MicroRNA microarray identifies Let-7i as a novel biomarker and therapeutic target in human epithelial ovarian cancer. , 2008, Cancer research.
[43] Peter A. Jones,et al. Epigenetics in cancer. , 2010, Carcinogenesis.
[44] Alicia Algeciras-Schimnich,et al. Two CD95 tumor classes with different sensitivities to antitumor drugs , 2003, Proceedings of the National Academy of Sciences of the United States of America.
[45] S. Canevari,et al. Cellular FLICE-inhibitory protein (c-FLIP) signalling: a key regulator of receptor-mediated apoptosis in physiologic context and in cancer. , 2010, The international journal of biochemistry & cell biology.
[46] C. Croce,et al. miR-15 and miR-16 induce apoptosis by targeting BCL2. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[47] R. Ozols,et al. Focus on epithelial ovarian cancer. , 2004, Cancer cell.
[48] Ie-Ming Shih,et al. The Origin and Pathogenesis of Epithelial Ovarian Cancer: A Proposed Unifying Theory , 2010, The American journal of surgical pathology.
[49] Patricia A. Kruk,et al. MicroRNA expression profiling in human ovarian cancer: miR-214 induces cell survival and cisplatin resistance by targeting PTEN (Cancer Research (2008) 68, (425-433)) , 2008 .
[50] W. Filipowicz,et al. Mechanisms of post-transcriptional regulation by microRNAs: are the answers in sight? , 2008, Nature Reviews Genetics.
[51] S. Memarzadeh,et al. Advances in the management of epithelial ovarian cancer. , 2001, The Journal of reproductive medicine.
[52] A. Berchuck,et al. Expression signatures of TP53 mutations in serous ovarian cancers , 2010, BMC Cancer.
[53] P. Gunaratne,et al. Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers. , 2010, Cancer research.
[54] S. Cory,et al. The Bcl2 family: regulators of the cellular life-or-death switch , 2002, Nature Reviews Cancer.
[55] Andreas Villunger,et al. p53- and Drug-Induced Apoptotic Responses Mediated by BH3-Only Proteins Puma and Noxa , 2003, Science.
[56] R. Chen,et al. Regulation of IKKβ by miR-199a affects NF-κB activity in ovarian cancer cells , 2008, Oncogene.
[57] Mariarosaria Incoronato,et al. miR-212 increases tumor necrosis factor-related apoptosis-inducing ligand sensitivity in non-small cell lung cancer by targeting the antiapoptotic protein PED. , 2010, Cancer research.
[58] G. Packham,et al. MicroRNAs: key players in carcinogenesis and novel therapeutic targets. , 2009, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[59] P. Krammer,et al. Death receptors in chemotherapy and cancer , 2004, Oncogene.
[60] D. Bartel. MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.
[61] Xin Zhang,et al. p53-Responsive micrornas 192 and 215 are capable of inducing cell cycle arrest. , 2008, Cancer research.
[62] S. Cohen,et al. microRNA functions. , 2007, Annual review of cell and developmental biology.
[63] Francesca Meloni,et al. An emerging player in the adaptive immune response: microRNA-146a is a modulator of IL-2 expression and activation-induced cell death in T lymphocytes. , 2010, Blood.
[64] Alice Shapiro,et al. MicroRNA-21 targets a network of key tumor-suppressive pathways in glioblastoma cells. , 2008, Cancer research.
[65] J. Wiezorek,et al. Death Receptor Agonists as a Targeted Therapy for Cancer , 2010, Clinical Cancer Research.
[66] A. Jemal,et al. Cancer Statistics, 2010 , 2010, CA: a cancer journal for clinicians.
[67] C. Croce,et al. MicroRNAs as regulators of death receptors signaling , 2010, Cell Death and Differentiation.
[68] T. Kwok,et al. Let-7a microRNA suppresses therapeutics-induced cancer cell death by targeting caspase-3 , 2008, Apoptosis.
[69] L. De Cecco,et al. Role of microRNAs in ovarian cancer pathogenesis and potential clinical implications. , 2010, The international journal of biochemistry & cell biology.
[70] M. Peter,et al. Two CD95 (APO‐1/Fas) signaling pathways , 1998, The EMBO journal.
[71] P. Morin,et al. MicroRNAs in ovarian carcinomas. , 2010, Endocrine-related cancer.
[72] G. Gores,et al. mir-29 regulates Mcl-1 protein expression and apoptosis , 2007, Oncogene.
[73] M. Gariboldi,et al. Molecular predictors of response and outcome in ovarian cancer. , 2006, Critical reviews in oncology/hematology.
[74] B. Tsang,et al. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. , 2008, Cancer research.
[75] D. Green,et al. Mitochondria and cell death: outer membrane permeabilization and beyond , 2010, Nature Reviews Molecular Cell Biology.
[76] E. Berns,et al. MicroRNAs in ovarian cancer biology and therapy resistance. , 2010, The international journal of biochemistry & cell biology.
[77] Kailai Sun,et al. MiR‐125b targets BCL3 and suppresses ovarian cancer proliferation , 2011, International journal of cancer.
[78] Sun-Mi Park,et al. microRNAs and death receptors. , 2008, Cytokine & growth factor reviews.
[79] John Calvin Reed,et al. FAP-1: a protein tyrosine phosphatase that associates with Fas. , 1995, Science.
[80] M. McKay,et al. Cancer of the ovary. , 1994, The New England journal of medicine.
[81] I Vergote,et al. The molecular genetic basis of ovarian cancer and its roadmap towards a better treatment. , 2010, Gynecologic oncology.
[82] A. Levine,et al. Surfing the p53 network , 2000, Nature.
[83] A. Hatzigeorgiou,et al. A guide through present computational approaches for the identification of mammalian microRNA targets , 2006, Nature Methods.